Company Participation in Industry Conference - Viatris Inc will participate in the Jeffries Global Healthcare Conference on June 6, 2024, in New York [1] - CEO Scott A Smith and company executives will engage in a fireside chat at 8 am ET during the conference [1] - A live webcast of the event will be available at investor viatris com, with an archived version accessible for a limited time post-event [2] Company Overview and Market Position - Viatris Inc is a global healthcare company uniquely positioned to bridge the gap between generics and brands [3] - The company supplies high-quality medicines to approximately 1 billion patients annually worldwide [3] - Viatris operates with a mission to empower people globally to live healthier at every stage of life, addressing healthcare needs from birth to end-of-life care [3] - The company boasts an extensive and diverse portfolio of medicines, a unique global supply chain, and scientific expertise to tackle enduring health challenges [3] - Viatris is headquartered in the US, with global centers in Pittsburgh, Shanghai, and Hyderabad, India [3]

DNY59 In our last coverage of Viatris Inc. (NASDAQ?VTRS) we pointed out that the company was the epitome of a value trap. It looked cheap and appealed to the "low "P/E" crowd. But the melting ice cube prevented any returns for all but those that bought the extreme dips and sold the minor rips. The chart below shows the performance of VTRS and its predecessor, Mylan Labs. Mylan Labs was combined with the generic unit of Pfizer Inc. (PFE) and started trading as VTRS in November 2020. VAI Viatris Inc (VTRS) Pr ...

Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impact PITTSBURGH, May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building ...

Viatris Inc. (NASDAQ:VTRS) BofA Securities 2024 Health Care Conference May 14, 2024 1:00 PM ET Company Participants Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Jason Gerber - BoA Securities Jason Gerber All right, everybody, we're going to get going here with our next company presenter at the Bank Of America Annual Healthcare Conference. We got Viatris. And joined with us is CFO, Doretta Mistras, and Philippe Martin, Chief R&D Officer. So thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other juris ...

Viatris Inc. (VTRS) delivered adjusted earnings of 67 cents per share in the first quarter of 2024, missing the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 77 cents in the year-ago quarter.Total revenues came in at $3.66 billion, down 1.7% year over year. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.7 million.Viatris’ stock is trading down in response to the first-quarter results mainly due to a miss on both earn ...

Viatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call Transcript May 9, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Conference Call Participants Nathan Rich - Goldman Sachs Bhavin Patel - Bank of America Glen Santangelo - Jefferies Ash Verma - UBS Chris Schott - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning and welcome to Viatris Q1 2024 Earnings Conference Call. ...

For the quarter ended March 2024, Viatris (VTRS) reported revenue of $3.66 billion, down 1.8% over the same period last year. EPS came in at $0.67, compared to $0.78 in the year-ago quarter. The reported revenue represents a surprise of -2.12% over the Zacks Consensus Estimate of $3.74 billion. With the consensus EPS estimate being $0.68, the EPS surprise was -1.47%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.47%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.67 per share when it actually produced earnings of $0.61, delivering a surprise of -8.96%.Over the last four quarters, the compan ...

Lara Ramsburg Chief Corporate Affairs Officer Brian Roman Chief Legal Officer Q1 2024 Select Key Product Net Sales, on a Consolidated Basis 22 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Full-Year 2024 Guidance Items as of May 9, 2024(1) | --- | --- | |--------------------- ...